Login to Your Account


Cellzome Lands Big GSK Deal: €475M for Inflammatory Diseases

By Nuala Moran


Wednesday, March 10, 2010

LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International)

 

BioWorld International Correspondent

 

To continue reading subscribe now to BioWorld International

Learn More about BioWorld International

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.